Share-based Payment Arrangement, Expense of TG THERAPEUTICS, INC. from 31 Dec 2013 to 30 Jun 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
TG THERAPEUTICS, INC. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2013 to 30 Jun 2025.
  • TG THERAPEUTICS, INC. Share-based Payment Arrangement, Expense for the quarter ending 30 Jun 2025 was $16,400,000, a 73% increase year-over-year.
  • TG THERAPEUTICS, INC. Share-based Payment Arrangement, Expense for the twelve months ending 30 Jun 2025 was $55,100,000, a 47% increase year-over-year.
  • TG THERAPEUTICS, INC. annual Share-based Payment Arrangement, Expense for 2024 was $42,500,000, a 12% increase from 2023.
  • TG THERAPEUTICS, INC. annual Share-based Payment Arrangement, Expense for 2023 was $37,900,000, a 15% decline from 2022.
  • TG THERAPEUTICS, INC. annual Share-based Payment Arrangement, Expense for 2022 was $44,600,000, a 27% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

TG THERAPEUTICS, INC. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q2 2025 $55,100,000 $16,400,000 +$6,900,000 +73% 01 Apr 2025 30 Jun 2025 10-Q 08 Aug 2025 2025 Q2
Q1 2025 $48,200,000 $15,000,000 +$5,700,000 +61% 01 Jan 2025 31 Mar 2025 10-Q 09 May 2025 2025 Q1
Q4 2024 $42,500,000 $11,900,000 +$2,500,000 +27% 01 Oct 2024 31 Dec 2024 10-K 03 Mar 2025 2024 FY
Q3 2024 $40,000,000 $11,800,000 +$2,600,000 +28% 01 Jul 2024 30 Sep 2024 10-Q 07 Nov 2024 2024 Q3
Q2 2024 $37,400,000 $9,500,000 -$3,000,000 -24% 01 Apr 2024 30 Jun 2024 10-Q 08 Aug 2025 2025 Q2
Q1 2024 $40,400,000 $9,300,000 +$2,500,000 +37% 01 Jan 2024 31 Mar 2024 10-Q 09 May 2025 2025 Q1
Q4 2023 $37,900,000 $9,400,000 01 Oct 2023 31 Dec 2023 10-K 03 Mar 2025 2024 FY
Q3 2023 $9,200,000 +$2,200,000 +31% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $12,500,000 01 Apr 2023 30 Jun 2023 10-Q 09 Aug 2024 2024 Q2
Q1 2023 $6,800,000 01 Jan 2023 31 Mar 2023 10-Q 06 May 2024 2024 Q1
Q3 2022 $7,000,000 01 Jul 2022 30 Sep 2022 10-Q 06 Nov 2023 2023 Q3
Q1 2016 $12,039,029 $1,698,965 -$3,658,063 -68% 01 Jan 2016 31 Mar 2016 10-Q 10 May 2016 2016 Q1
Q4 2015 $15,697,092 $2,857,044 01 Oct 2015 31 Dec 2015 10-K 16 Mar 2017 2016 FY
Q3 2015 $1,240,034 01 Jul 2015 30 Sep 2015 10-Q 09 Nov 2015 2015 Q3
Q2 2015 $6,242,986 01 Apr 2015 30 Jun 2015 10-Q 10 Aug 2015 2015 Q2
Q1 2015 $5,357,028 01 Jan 2015 31 Mar 2015 10-Q 10 May 2016 2016 Q1

TG THERAPEUTICS, INC. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $42,500,000 +$4,600,000 +12% 01 Jan 2024 31 Dec 2024 10-K 03 Mar 2025 2024 FY
2023 $37,900,000 -$6,700,000 -15% 01 Jan 2023 31 Dec 2023 10-K 03 Mar 2025 2024 FY
2022 $44,600,000 -$16,700,000 -27% 01 Jan 2022 31 Dec 2022 10-K 03 Mar 2025 2024 FY
2021 $61,300,000 01 Jan 2021 31 Dec 2021 10-K 29 Feb 2024 2023 FY
2019 $11,335,000 -$1,551,000 -12% 01 Jan 2019 31 Dec 2019 10-K 02 Mar 2020 2019 FY
2018 $12,886,000 -$3,059,000 -19% 01 Jan 2018 31 Dec 2018 10-K 02 Mar 2020 2019 FY
2017 $15,945,000 +$8,435,000 +112% 01 Jan 2017 31 Dec 2017 10-K 02 Mar 2020 2019 FY
2016 $7,510,000 -$8,187,092 -52% 01 Jan 2016 31 Dec 2016 10-K 01 Mar 2019 2018 FY
2015 $15,697,092 -$5,408,200 -26% 01 Jan 2015 31 Dec 2015 10-K 16 Mar 2017 2016 FY
2014 $21,105,292 +$15,902,144 +306% 01 Jan 2014 31 Dec 2014 10-K 16 Mar 2017 2016 FY
2013 $5,203,148 01 Jan 2013 31 Dec 2013 10-K 15 Mar 2016 2015 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.